Pomerantz Law Firm Alert: Class Action Against BioAge Labs for Securities Fraud

Pomerantz Law Firm Issues Class Action Alert for BioAge Labs Shareholders

Pomerantz LLP has recently announced the filing of a class action lawsuit against BioAge Labs, Inc. (NASDAQ: BIOA), aimed at shareholders who have experienced losses related to their investment in the company. Investors who purchased BioAge securities during the designated class period are encouraged to act swiftly as critical deadlines are approaching.

Overview of the Class Action

Shareholders affected by potential securities fraud and wrongful business practices by BioAge are urged to contact the Pomerantz team. Danielle Peyton, an attorney from the firm, can be reached at [email protected] or toll-free at 888-4-POMLAW, Ext. 7980. When reaching out via email, investors should include their mailing addresses, phone numbers, and the quantity of shares they acquired.

The class action revolves around allegations that BioAge, alongside certain of its officers and directors, may have engaged in unlawful acts that misled investors. Those affected have until March 10, 2025, to request the court appoint them as Lead Plaintiff if they meet the necessary criteria. Individuals interested in the specifics of the lawsuit can find a copy of the Complaint at Pomerantz Law Firm's website.

Significant Events for BioAge Labs

BioAge Labs recently made headlines when it conducted its initial public offering (IPO) on September 26, 2024, offering 12.65 million shares at an enthusiastic price of $18.00 per share. However, things took a downturn after an announcement on December 6, 2024, stated that the company would halt its ongoing STRIDES Phase 2 study of azelaprag, its investigational drug candidate. This decision was prompted by observations of liver transaminitis in several trial participants. Following this news, BioAge’s stock plummeted by $15.44, representing a staggering decline of 76.85%, closing at $4.65 per share on December 9, 2024.

About Pomerantz LLP

Renowned as a leader in corporate, securities, and antitrust class action litigation, Pomerantz LLP was established over 85 years ago by the late Abraham L. Pomerantz. Celebrated as a pioneering figure in the field of securities class actions, Pomerantz has continued his legacy by advocating for victims of fraud and corporate misconduct. The firm has a proven track record of securing substantial damages for individuals affected by securities fraud.

With offices located in major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz has become a trusted name in legal representation, consistently dedicated to fighting for investor rights. The firm notably emphasizes transparency and accessibility for those seeking to join a class action.

Final Thoughts

As the deadline for participation in this class action approaches, affected shareholders should not hesitate to reach out. This legal step is crucial in holding companies accountable and reclaiming losses associated with investments. Affected investors are encouraged to stay informed and assert their rights through this opportunity.

For additional inquiries or assistance, please contact Danielle Peyton at Pomerantz LLP, where commitment to client advocacy remains at the forefront of their practice.